The Science Behind The Pain Block™ System
Auxesis Pharma is developing a Swedish technology platform for the local treatment of pain, irritation and skin-related conditions.
The Pain Block™ system combines established science with innovative topical formulations, creating opportunities across both pharmaceuticals and dermatology.
From one shared technology platform, we are building a growing portfolio for human healthcare, veterinary medicine and professional skin care.
Swedish research with the skin as the starting point
Auxesis Pharma's research is based on a simple principle: pain and irritation that originate locally in the skin should be treated locally. Topical application enables treatment to be directed to the area where the problem occurs.
A central part of our technology platform is stabilized acetylsalicylic acid (ASA) in liquid form. ASA is a well-established substance with analgesic and anti-inflammatory properties.
The technology creates a foundation for several product categories – from over-the-counter and prescription medicines to veterinary medicine, dermatology and cosmeceuticals.
Development takes place in Sweden together with specialized partners in formulation, regulatory strategy and clinical drug development.
The platform enables development within:
- local skin pain and irritation
- OTC treatments for skin-related conditions
- prescription topical medicines
- dermatology and medical skin care
- veterinary medicine
One Technology Platform – Multiple Treatment Opportunities
Acetylsalicylic acid (ASA) is a well-known and well-established substance. Auxesis Pharma has developed a formulation technology that makes it possible to keep ASA stable in liquid form for topical use.
The stabilized formulation is designed for local penetration into the skin and targeted action at the area where pain and irritation occur.
One innovation can form the basis for multiple products, indications and commercial brands.
How localized COX-2 inhibition works in the skin
How Does the Local Pain Signal Arise?
When the skin is irritated or affected by tissue injury, COX-related processes are activated and contribute to pain and inflammation.
- Pain: COX signals contribute to local pain signaling.
- Inflammation: The COX system plays a central role in the inflammatory process.
Targeted Local Action
ASA.P® is designed to act locally at the area where pain and irritation occur:
- Applied directly to the affected skin area
- Targeted local action at the source of pain
- Reduces the need for systemic administration
From Formulation to Clinical Validation
ASA.P® is Auxesis Pharma's first pharmaceutical product based on the technology platform. The development program has progressed from formulation and stability work to regulatory and clinical development.
- the drug formulation has been finalized together with Zelmic
- regulatory development is carried out together with RegSmart Life Science
- clinical study protocols and the clinical program are being developed together with CTC
- clinical studies are planned in Uppsala involving healthy volunteers
During 2026, ASA.P® advances into clinical development. The first clinical phase is focused on creating clinical and regulatory validation of the topical formulation.
The study program involves healthy volunteers and is intended to build the evidence required for Proof of Concept and continued regulatory development.
Following clinical validation, the next steps include continued regulatory work, preparations for market authorization and the establishment of a future licensing partner.
What the Clinical Development Is Designed to Verify
The clinical program focuses on three central areas:
Local penetration and exposure in the skin
Intended local effect on pain and irritation
Safety and limited systemic exposure
ASA.P® – Human Healthcare
ASA.P® is Auxesis Pharma's first topical pharmaceutical product for the local treatment of skin pain and irritation.
Discover ASA.P®CoxyPet® – Animal Healthcare
CoxyPet® builds on the same scientific foundation as our human formulations and is being developed for the local treatment of pain and irritation in animals.
Discover CoxyPet®Specialized Partners Throughout the Development Chain
Auxesis Pharma works with established Swedish specialists in formulation, regulatory processes and clinical development.
- Zelmic – formulation and development of topical pharmaceuticals
- RegSmart Life Science – regulatory strategy and authority processes
- CTC – clinical development and execution of clinical studies
The partnership model provides access to specialized expertise throughout the development chain and creates a capital-efficient pathway from research to market.
RegSmart Life Science
RegSmart Life Science stödjer Auxesis Pharma inom regulatorisk strategi, klinisk utveckling och myndighetsprocesser. Samarbetet omfattar bland annat regulatoriska protokoll, kliniska studieansökningar och internationell regulatorisk planering.
Besök RegSmart
Zelmic
Zelmic är specialist inom topikala och transdermala läkemedelsformuleringar och stödjer Auxesis Pharma i formulering, stabilitet och produktutveckling.
Besök Zelmic
CTC
CTC stödjer Auxesis Pharma inom klinisk läkemedelsutveckling och genomförande av kliniska studier. Samarbetet omfattar bland annat kliniska protokoll och studier i Uppsala.
Besök CTCOne Platform with Multiple Product Opportunities
The Pain Block™ system is designed as a scalable technology platform. The same scientific and technical foundation can be used to develop multiple products across different market segments.
The portfolio includes pharmaceuticals in pain management and veterinary medicine as well as dermatology and cosmeceutical products – with the potential to create additional products and commercial brands over time.
Explore Our Product Portfolio
A Growing International IP Platform
Auxesis Pharma is building international intellectual property protection around the technology platform and future product areas. ASA.P® is covered by two PCT patent applications, with geographic expansion across Europe, the US, Japan, China, South Korea and Australia.
The IP portfolio also includes new patent programs for Opirexa™ and future medical treatment of keratosis, together with more than 90 trademark registrations across 45 countries.
From One Innovation to a Diversified Portfolio
Auxesis Pharma is building a House of Brands in which one shared technology platform supports products across Pharmaceuticals and Dermatology.
The portfolio includes ASA.P®, Opirexa™, Derivexa™, CoxyPet®, Cutivelle™ and Lenvée™ – with potential for additional products, indications and strategic partnerships.
Explore Our PipelineFrom Research to Market
Auxesis Pharma works step by step from scientific research and formulation to regulatory validation, clinical development and commercialization.
Our goal is to develop new local treatments that address clear needs within pain, dermatology and veterinary medicine – while building a platform that can scale internationally.